Article Information
History
- October 2, 2020.
Article Versions
- Version 1 (August 4, 2020 - 06:50).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Jian-Guo Zhou*,1,2,3,
- Anna-Jasmina Donaubauer*,1,2,
- Benjamin Frey1,2,
- Ina Becker1,2,
- Sandra Rutzner1,2,
- Markus Eckstein2,4,
- Roger Sun5,6,
- Hu Ma3,
- Philipp Schubert1,2,
- Claudia Schweizer1,2,
- Rainer Fietkau1,2,
- Eric Deutsch5,6,
- Udo S. Gaipl#,1,2,+ and
- Markus Hecht#,1,2
- 1Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangenw, Germany
- 2Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
- 3Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China
- 4Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- 5Department of Radiation Oncology, Gustave Roussy-CentraleSupélec-TheraPanacea Center of Artificial Intelligence in Radiation Therapy and Oncology, Gustave Roussy, Villejuifw, France
- 6Université Paris-Saclay, INSERM1030 Radiothérapie Moléculaire, Villejuif France
- ↵+Corresponding author: Prof. Dr. Udo S. Gaipl, Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Universitätsstraße 27, 91054 Erlangen, Germany, Tel.: +49 9131 85 44258; Fax: +49 9131 85 39335, E-mail address: udo.gaipl{at}uk-erlangen.de.
Posted October 02, 2020.
Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of metastatic cancer patients to immune checkpoint inhibitors
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos